We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00033202
First Posted: April 10, 2002
Last Update Posted: June 3, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Rhode Island Hospital
Dana-Farber Cancer Institute
Information provided by:
Sigma-Tau Research, Inc.
April 9, 2002
April 10, 2002
June 3, 2009
March 2002
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00033202 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor
Phase I Study of Oral ST1481 Administered Once Weekly Every 3 Out 4 Weeks in Patients With Advanced Solid Malignancies.
Gimatecan® is sigma-tau Research's new, potent, oral Topoisomerase I inhibitor. Drugs in this class play a crucial role in destroying DNA replication in tumors. We are conducting this study to determine the Maximum Tolerated Dose of our compound, when given as a capsule, rather than by intravenous injection.
Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Solid Malignancies
Drug: Gimatecan® (ST-1481)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
February 2005
Not Provided

Inclusion criteria:

  • Histologically/cytologically proven advanced solid tumors
  • Life expectancy of at least 3 months with normal hematological, liver and renal function

Exclusion criteria:

  • Pregnant and lactating patients
  • Participation in any investigating drug study within 4 weeks preceding treatment start or concurrent treatment with any other anti-cancer therapy
  • Gastrointestinal dysfunction that could alter absorption or motility
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00033202
ST 01-401
Not Provided
Not Provided
Not Provided
Not Provided
Sigma-Tau Research, Inc.
  • Rhode Island Hospital
  • Dana-Farber Cancer Institute
Not Provided
Sigma-Tau Research, Inc.
June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP